Glycemic Control in Adult Surgical Patients Receiving Regular Insulin Added to Parenteral Nutrition vs Insulin Glargine: A Retrospective Chart Review. (29th January 2019)

• Record Type: Journal Article
• Authors: Truong, Stephanie; Park, Annie; Kamalay, Salem; Hung, Nancy; Meyer, Jesse G.; Nguyen, Nicole; Momenzadeh, Amanda
• Is Part Of: Nutrition in clinical practice. Volume 34:Number 5(2019)
• Page Start: 775
• Page End: 782
• Publication Date: 2019-01-29
• Subjects: diabetes mellitus -- glycemic control -- hyperglycemia -- insulin -- nutrition support -- parenteral nutrition; Nutrition -- Periodicals; Diet therapy -- Periodicals; Artificial feeding -- Periodicals; 615.854
• DOI: 10.1002/ncp.10252
• Languages: English
• ISSNs: 0884-5336

Abstract

Abstract: Background: Hyperglycemia is a frequent complication in patients receiving parenteral nutrition (PN) and has been associated with an increased risk of mortality. Treatment of hyperglycemia requires insulin therapy; however, the optimal dose and route have not been established. This study aimed to compare regular insulin added to PN (RI‐in‐PN) with subcutaneous insulin glargine for the management of hyperglycemia in patients receiving PN. Methods: This retrospective study was conducted at a tertiary medical center and reviewed 113 adult, non–critically ill surgical patient admissions receiving PN over a 5‐year period. The primary outcome was achievement of glycemic control. Secondary outcomes were time to glycemic control, hypoglycemic events, hospital length of stay, and 1‐year mortality. Results: The RI‐in‐PN group had a significantly higher percentage of patient admissions who achieved glycemic control compared with the insulin glargine group (71.8% vs 48.6%, P = 0.017). There was no difference in time to glycemic control, hypoglycemic events, hospital length of stay, or 1‐year mortality between groups. Among patients with diabetes mellitus (DM), however, the insulin glargine group had a significantly higher percentage of admissions with at least 1 hypoglycemic event (45.5% vs 20%, P = 0.035). Conclusions: RI‐in‐PN is recommended over insulin glargine because of the higher likelihood of achieving glycemic control and, in patients with DM, lower risk of hypoglycemic events. Large, randomized controlled trials are needed to further guide prescribing practice.